Fresh off a second quarter featuring what Exelixis Inc. CEO Michael Morrissey called "strong momentum" for its lead product, Cabometyx (cabozantinib), the California company has inked a multimillion-dollar oncology deal with Bangalore, India-based Aurigene Discovery Technologies Ltd., a small-molecule specialist owned by Dr. Reddy's Laboratories Ltd.